Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease

Inclusion Criteria: * Age from 18-85 years old, male or nonpregnant women * asymptomatic ischemia, stable or unstable angina, old myocardial infarction patients * at least one target lesion length ≥ 20 mm (Visual method) * Target lesion diameter 2.5mm-4.0 mm (Visual method) * Target lesion diameter stenosis ≥ 70% * Patients who has indications for coronary artery bypass graft (CABG) surgery * Patients who is voluntary, understand the purpose of the study, willing to accept angiography and clinical follow-up Exclusion Criteria: * Acute myocardial infarction for less than 1 week * Bridge vascular disease * In-stent restenosis lesions * Patient with bleeding tendency, history of active peptic ulcer, History of cerebral hemorrhage or subarachnoid hemorrhage, history of stroke within half year, contraindications to anticoagulant therapy and antiplatelet * Allergic to aspirin, clopidogrel or ticlopidine, heparin, contrast agent, rapamycin and metal * Life expectancy is less than 12 months * Patient who has participated in other clinical trials but does not meet the deadline of the primary endpoint * Poor patient compliance * Heart transplant recipient * Patient who had other stent implanted within 1 year * Patient who has multi-vessel disease(Long lesions) and has already received other stent implantation